Welcome to our dedicated page for United Guardian SEC filings (Ticker: UG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The United-Guardian, Inc. (NASDAQ: UG) SEC filings page brings together the company’s regulatory disclosures, including annual, quarterly, and current reports filed with the U.S. Securities and Exchange Commission. These documents provide detailed information on United-Guardian’s operations as a manufacturer of cosmetic ingredients, pharmaceuticals, medical lubricants, and sexual wellness ingredients.
In its periodic reports, such as Form 10-K and Form 10-Q, United-Guardian presents financial statements that break out net sales, cost of sales, operating expenses, and research and development expense. Investors can see how revenue and profitability relate to the company’s four main product categories and review line items such as investment income and gains or losses on marketable securities. These filings also discuss factors that influence results, including distributor demand and supply conditions for key products like Renacidin.
Form 8-K current reports are used by United-Guardian to furnish press releases on results of operations and financial condition and to provide Regulation FD disclosures for events such as dividend declarations. Recent 8-K filings reference attached press releases that describe quarterly performance and Board decisions on cash dividends.
On this page, AI-powered tools can help interpret lengthy filings by highlighting key sections, summarizing changes in sales and expenses, and clarifying the significance of items such as research and development spending or other income. Users can quickly locate references to product categories, dividend policies, and projects related to Renacidin and personal care products, while real-time updates ensure that new United-Guardian filings from EDGAR are available as they are submitted.
United-Guardian, Inc. filed a current report to furnish information under Regulation FD. The company stated that on January 29, 2026 it issued a press release, which is attached to the report as Exhibit 99.1 and incorporated by reference for public disclosure.
United-Guardian director Kenneth H. Globus reported a family stock gift involving shares deemed beneficially owned by him. On January 21, 2026, 7,480 shares of United-Guardian, Inc. common stock that were owned by his wife were gifted by her to their grandson at a price of $0 per share, reflecting a non-cash transfer reported with code G. The shares are included on this Form 4 because his spouse’s holdings are treated as being beneficially owned by him.
After this transaction, the filing states that Globus’s beneficial ownership consists of 279,027 shares held directly and 1,031,546 shares held indirectly. Of the indirect amount, 271,546 shares are owned by his wife and 760,000 shares are controlled by him as co‑trustee of the Alfred R. Globus Testamentary Trust, which is treated as beneficially owned due to his voting authority.
United-Guardian (UG) filed its Q3 2025 10-Q reporting lower sales and earnings. Net sales were $2,264,261, down from $3,060,113 a year ago, with nine‑month sales at $7,583,613 versus $9,705,262. Net income was $268,441 in the quarter (vs. $865,484) and $1,456,162 year‑to‑date (vs. $2,747,151). EPS was $0.06 for the quarter (vs. $0.19) and $0.32 year‑to‑date (vs. $0.60).
Mix and volume pressures weighed on margins: cost of sales rose to 58% of sales in Q3 (46% prior year) and to 50% for the nine months (47% prior year), reflecting a higher contribution from lower‑margin pharmaceuticals and lower cosmetic volumes. Cosmetic ingredient sales softened, particularly tied to China demand and tariff dynamics, while pharmaceuticals grew on both a gross and net basis.
Operating cash flow was $1,636,324 for the nine months. The company paid cash dividends of $0.35 per share in February and $0.25 per share in August. Management highlighted ongoing tariff uncertainty related to China and noted the Natrajel launch timing has shifted to 2026 due to customer timelines. Working capital remains strong with a 7.0:1 current ratio.
United-Guardian, Inc. filed a current report to note that it released an earnings-related press release. Under the item covering results of operations and financial condition, the company states that on November 6, 2025 it issued a press release, which is attached as Exhibit 99.1 and incorporated by reference. The filing itself does not include the detailed financial results, directing readers instead to the attached exhibit for full information.
United-Guardian (UG) posted softer Q2 FY25 results amid tariff-related demand weakness in Asia. Net sales fell 16% YoY to $2.84 m, pulling H1 revenue down 20% to $5.32 m. Cosmetic ingredients—heavily exposed to China through key distributor ASI—dropped 37% in the quarter, while pharmaceuticals rose 3% and medical lubricants slid 12%.
Gross margin held near 53%, but a 15% rise in operating expenses cut operating profit 38% to $0.70 m. Net income declined 34% to $0.63 m (EPS $0.14); H1 earnings were 37% lower at $1.19 m (EPS $0.26).
Operating cash flow shrank to $0.63 m from $1.97 m. Cash, equivalents and marketable securities total $8.42 m, supporting a 6.7× current ratio and debt-free balance sheet. Retained earnings eased after a $0.35/share dividend paid in Feb; another $0.25/share dividend was declared 11 Jul 25 for payment on 1 Aug 25.
Management flags heightened risk from new U.S. tariffs effective Aug-25 and possible Chinese retaliation, given ~40% of ASI resale volume is China-bound. Customer (one distributor 75%+) and supplier concentration remain structural risks. The company expects its new Natrajel sexual-wellness line to begin contributing in H2 25, offering a prospective growth lever.
United-Guardian, Inc. filed a current report describing the release of a press announcement about its results of operations and financial condition. The company stated that it issued this press release on August 8, 2025, and attached it as an exhibit for investors and the public to review.